Identification of New Malaria Parasite Erythrocyte Binding Protein (BAEBL) that Binds to Human Red Cells
Description of Invention:
Malaria is endemic in many parts of the world, particularly in tropical regions such as Asia, Central America and South America. Recent estimates of the number of cases of malaria worldwide are between five hundred million and one billion. There are approximately two to three hundred million new cases of malaria each year and malaria causes a minimum of one million deaths each year. This invention relates to the identification and characterization of the binding specificity of BAEBL, a novel Plasmodium falciparum erythrocyte binding ligand that interacts with human erythrocytes in a sialic acid dependent manner. This novel Plasmodium falciparum erythrocyte binding ligand is unique and quite distinct from previously described Plasmodium falciparum erythrocyte binding proteins EBA-175. BAEBL may be used as a malaria vaccine to block human red cell recognition and invasion.
Inventors:
Ghislaine D. Mayer and Louis H. Miller (NIAID)
Patent Status:
DHHS Reference No. E-328-2000/0 --
U.S. Provisional Application No. 60/281,130 filed 02 Apr 2001
PCT Application No. PCT/US02/10071 filed 29 Mar 2002, which published as WO 02/078603 on 10 Oct 2002
U.S. Patent Application No. 10/677,980 filed 02 Oct 2003
Portfolios: Infectious Diseases
Infectious Diseases -Vaccines
For Additional Information Please Contact: Robert M. Joynes J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)594-6565
Email: joynesr@mail.nih.gov
Fax: (301) 402-0220
